REGENERON PHARMACEUTICALS, INC. ·
REGN 8-K 2026-10-06
REGENERON PHARMACEUTICALS, INC. (REGN) 8-K dated 2026-10-06 — accession 0001104659-26-113895. This URL is the filing, not the REGN hub.
REGENERON PHARMACEUTICALS, INC. (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
REGN to acquire platform ($22M)
Cached items: 1.01, 2.02, 8.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 18.3.
Not investment advice. The REGN SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”)
- Deal
- $22M
Why it matters
- expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”)
- Transaction value about $22M